Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs.
Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans S, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG, Nambiar S, Kim P, Boucher HW. Kinamon T, et al. Clin Infect Dis. 2023 Aug 22;77(4):649-656. doi: 10.1093/cid/ciad239. Clin Infect Dis. 2023. PMID: 37073571 Free PMC article.
A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection.
Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler VG Jr, Boucher HW, Evans SR, Paul M, Holland TL, Doernberg SB. Howard-Anderson J, et al. Open Forum Infect Dis. 2022 Apr 9;9(6):ofac140. doi: 10.1093/ofid/ofac140. eCollection 2022 Jun. Open Forum Infect Dis. 2022. PMID: 35615299 Free PMC article.
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Hill C, Gelone SP, Mariano D, Baba T, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW. Howard-Anderson J, et al. Clin Infect Dis. 2023 Feb 8;76(3):e1157-e1165. doi: 10.1093/cid/ciac692. Clin Infect Dis. 2023. PMID: 36031403 Free PMC article.
Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Leister-Tebbe H, Hill C, Geres H, Holland TL, Doernberg SB, Chambers HF, Fowler VG Jr, Evans SR, Boucher HW; Antibacterial Resistance Leadership Group. Howard-Anderson J, et al. Clin Infect Dis. 2024 Feb 17;78(2):259-268. doi: 10.1093/cid/ciad576. Clin Infect Dis. 2024. PMID: 37740559
The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.
Evans SR, Patel R, Hamasaki T, Howard-Anderson J, Kinamon T, King HA, Collyar D, Cross HR, Chambers HF, Fowler VG, Boucher HW; Antibacterial Resistance Leadership Group. Evans SR, et al. Among authors: howard anderson j. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S321-S330. doi: 10.1093/cid/ciad538. Clin Infect Dis. 2023. PMID: 37843122
Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales.
Howard-Anderson JR, Earley M, Komarow L, Abbo L, Anderson DJ, Gallagher JC, Grant M, Kim A, Bonomo RA, van Duin D, Muñoz-Price LS, Jacob JT; Antibacterial Resistance Leadership Group. Howard-Anderson JR, et al. Infect Control Hosp Epidemiol. 2022 Dec;43(12):1840-1846. doi: 10.1017/ice.2022.4. Epub 2022 Feb 2. Infect Control Hosp Epidemiol. 2022. PMID: 35105408 Free PMC article.
45 results